Sugi Predict

Sugi Predict / Compounds / SCHEMBL6887420

SCHEMBL6887420

SCHEMBL6887420

CCCCC(=O)NS(C)(=O)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 2/20 0.55
▸ HSP90AA1 P07900 1/20 0.45
▸ PTGES O14684 1/20 0.44
▸ CES1 P23141 2/20 0.44
▸ CES2 O00748 1/20 0.44
▸ FAAH O00519 4/20 0.43
▸ CA1 P00915 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ MAPT P10636 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3354881 0.98 EPHX2 (0.54) EPHX2HSP90AA1PTGESCES1CES2
SCHEMBL2810388 0.93 EPHX2 (0.62) EPHX2HSP90AA1PTGESCES1CES2
SCHEMBL13188006 0.91 EPHX2 (0.65) EPHX2HSP90AA1PTGESCES1CES2
SCHEMBL18954224 0.91 EPHX2 (0.65) EPHX2HSP90AA1PTGESCES1CES2
SCHEMBL6015 0.86 HDAC3 (0.50) EPHX2PTGESCES1CES2CA1
SCHEMBL3477319 0.82 FNTA (0.46) EPHX2HSP90AA1CES1CES2FAAH
SCHEMBL7468860 0.82 HSP90AA1 (0.45) EPHX2HSP90AA1CES1CES2FAAH
SCHEMBL18954312 0.82 EPHX2 (0.81) EPHX2FAAHMAPTKMT2AMEN1
SCHEMBL16181434 0.80 CA1 (0.49) EPHX2HSP90AA1CES1CES2FAAH
SCHEMBL4001550 0.80 ALDH1A1 (0.44) EPHX2HSP90AA1CES1CES2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2004502669-A — — 2004-01-29 — — JP claimed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 — — EP claimed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 — — WO claimed
US-12371434-B2 MLL1 inhibitors and anti-cancer agents CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2025-07-29 — — US disclosed
US-20230121768-A1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2023-04-20 — — US disclosed
US-20230047296-A1 Nrf2 REGULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-02-16 — — US disclosed
US-11407721-B2 CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer AMGEN INC. (US) 2022-08-09 — — US disclosed
US-20180354918-A1 CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2018-12-13 — — US disclosed
EP-3277672-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2018-02-07 — — EP disclosed
EP-3277671-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2018-02-07 — — EP disclosed
EP-3277670-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2018-02-07 — — EP disclosed
US-20130267508-A1 BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS JANSSEN R&D IRELAND (IE) 2013-10-10 — — US disclosed
EP-0923562-B1 SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS BAYER AG (DE) 2002-10-09 — — EP disclosed
US-6444616-B1 HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 2002-09-03 — — US disclosed
CN-1077110-C 13-substituted milbemycin 5-oxime derivatives their preparation and their use against insects and other pests SANKYO CO (JP) 2002-01-02 — — CN disclosed
US-6130225-A Substituted p-trifluoromethylphenyluracils BAYER AKTIENGESELLSCHAFT (DE) 2000-10-10 — — US disclosed
EP-0923562-A1 SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS BAYER AG (DE) 1999-06-23 — — EP disclosed
WO-1998006706-A1 SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS BAYER AKTIENGESELLSCHAFT (DE) 1998-02-19 — — WO disclosed
CN-1153177-A 13-substituted milbemycin 5-oxime derivatives their preparation and their use against insects and other pests SANKYO CO (JP) 1997-07-02 — — CN disclosed
EP-0054924-A2 Pharmaceutical compounds, their preparation and use THE WELLCOME FOUNDATION LIMITED (GB) 1982-06-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371434-B2 MLL1 inhibitors and anti-cancer agents MLLT1, BMI1, DOT1L EPHX2 2479/4885HSP90AA1 3203/4885PTGES 4513/4885
US-20180354918-A1 CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER MDM2, TP53, MDM4 EPHX2 2612/4885HSP90AA1 2618/4885PTGES 2805/4885
US-20130267508-A1 BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS SBDS, CHUK, HAT1 EPHX2 3294/4885HSP90AA1 4583/4885PTGES 989/4885
US-11407721-B2 CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer MDM2, TP53, MDM4 EPHX2 2612/4885HSP90AA1 2618/4885PTGES 2805/4885
US-20230047296-A1 Nrf2 REGULATORS NFE2L2, KEAP1, NQO1 EPHX2 996/4885HSP90AA1 1121/4885PTGES 138/4885
US-20230121768-A1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS MLLT1, BMI1, DOT1L EPHX2 2479/4885HSP90AA1 3203/4885PTGES 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.